Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breas
 

Celgene International SÃ*rl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

More...